Science-First Strategies To Advance Development And Approval Of Rare/Ultra-Rare Disease Therapies

At Veristat, we see facilitating success for our sponsors of rare disease therapy clinical trials as a fundamental responsibility. We’re a team of Science-First thinkers, never assuming a situation can be addressed as it has always been done before. Supporting the development of rare disease therapies accounts for 35% of Veristat’s work. From regulatory pathway selection to patient recruitment and site selection to collecting and cleaning the data, we plan your trial with the utmost precision and innovative approaches.

Our scientific experts account for your highly compromised study participants, leveraging the power of biostatistics to meet your trial’s objectives, regardless of the complexities.